Top California Lender Closes $17.8 Million Commercial Real Estate Acquisition Loan 22-07-2025, 02:35

Io Therapeutics, Inc., presented data from studies of IRX4204, the company’s phase II clinical development stage, highly selective third generation RXR nuclear receptor agonist compound, supporting its potential use for prevention and treatment of normal 10-07-2024, 07:00

AttackForge Launches Version 2 - Redefining Pentesting for the Future 24-01-2023, 22:15